Liver Abscess & Parasitic Liver Disease: Clinical Review

I. PYOGENIC LIVER ABSCESS (PLA)

Pathophysiology & Etiology

1. Biliary obstruction (cholelithiasis, malignancy, intrahepatic cholangiopathy post-transplant) — now the most frequent cause
2. Portal vein pyemia from ascending enteric infection (appendicitis, diverticulitis)
3. Trauma (blunt or penetrating)
4. Hematogenous seeding via the hepatic artery from systemic bacteremia
5. Cryptogenic (no identifiable source — frequently associated with Klebsiella pneumoniae)

Clinical Presentation

Diagnosis

• CT with IV contrast — most sensitive; abscesses appear hypoattenuated with possible loculations and peripheral rim enhancement (uncommon but specific for abscess)
• Ultrasound — less sensitive; preferred initial test in pediatrics; abscesses appear hypoechoic with possible internal echoes
• Laboratory: leukocytosis, elevated ALP, elevated bilirubin, transaminitis
• Blood cultures (positive in >50% of cases) and abscess cultures are essential
• Local inflammation can cause portal or hepatic vein thrombosis → portal hypertension or Budd-Chiari syndrome

CT images showing pyogenic liver abscess with rim enhancement — Current Surgical Therapy 14e

Ultrasound images of liver abscess

Treatment

• Broad-spectrum empiric coverage targeting aerobic enteric gram-negatives (E. coli, Klebsiella), gram-positives (streptococci), and enteric anaerobes
• Post-transplant patients: consider carbapenems for ESBL coverage
• Duration: guided by clinical response + abscess resolution on follow-up imaging at 4–6 weeks

• Recommended for any abscess >5 cm — superior outcomes vs needle aspiration alone
• Very large abscesses >10 cm may require multiple catheters but percutaneous drainage remains first-line
• Abscesses <3 cm: aspiration if technically feasible to guide antibiotic treatment
• Catheters remain until output is low and clear for several days
• Watch for bile in drain fluid (suggests biliary communication) → investigate with HIDA or MRCP/ERCP; may require sphincterotomy or percutaneous biliary drain

• Reserved for cases with abscess rupture, concurrent intraabdominal abscess, or failure of minimally invasive management
• Open drainage carries higher morbidity than percutaneous approach

II. AMOEBIC LIVER ABSCESS (ALA)

Pathophysiology

• Abscesses contain necrotic hepatocytes and trophozoites in thick, proteinaceous brown fluid — classically described as "anchovy paste"
• Rates of ALA are less than 1% of symptomatic enteric amebiasis

Clinical Presentation

• Fever (~80%), RUQ pain (~60%), leukocytosis, elevated ALP/bilirubin/transaminases
• Eosinophilia is not commonly seen despite parasitic cause
• Travel history and remote antecedent diarrheal illness are critical clues

Diagnosis

• Serology (antibody or antigen): highly sensitive, essential for diagnosis
  • Antigen testing is more specific than antibody serology
  • ~⅓ of patients with prior E. histolytica infection retain antibodies without active disease
  • >90% of patients with ALA have antibodies to E. histolytica in high titer
• Imaging (CT/US): cannot differentiate ALA from PLA
  • Multiple abscesses suggest pyogenic infection; ALA tends to be solitary
• Aspiration: "anchovy paste" fluid; finding cysts/trophozoites in stool supports diagnosis

Differential Diagnosis: ALA vs PLA

Differential Diagnosis (both types)

• Hepatic malignancy (necrotic center can mimic fluid-filled abscess)
• Cholangitis / cholecystitis
• Right lower lobe pneumonia
• Acute pancreatitis
• Perforated peptic ulcer

Treatment

• Clinical improvement (pain + fever reduction) in >90% of patients within 72 hours
• Longer-acting nitroimidazoles (tinidazole, ornidazole) effective as single-dose therapy

• Paromomycin 10 mg/kg three times daily for 7 days, OR
• Diiodohydroxyquin (iodoquinol) 650 mg three times daily for 20 days

1. Need to rule out pyogenic abscess (multiple lesions)
2. No clinical response within 3–5 days
3. Threat of imminent rupture
4. Left-lobe abscess threatening pericardial rupture

• No evidence that aspiration accelerates healing, even for large (up to 10 cm) abscesses
• Percutaneous drainage can be successful even after rupture

III. PARASITIC LIVER DISEASES — COMPLICATIONS

Hydatid (Echinococcal) Cyst Disease

• Rupture into the biliary tree (in ~⅓ of cases) — cholangitis, obstructive jaundice
• Rupture through the diaphragm into the pleural cavity
• Rupture into the peritoneum — anaphylaxis risk
• Secondary bacterial infection (pyogenic superinfection)
• Compression of hepatic vessels or bile ducts

• PAIR (Puncture-Aspiration-Injection-Re-aspiration) + albendazole for active CL/CE1/CE3 lesions; avoid for ALA due to anaphylaxis risk with echinococcal cysts
• Surgery + albendazole for complex, large, or complicated cysts
• Albendazole or mebendazole alone is less effective than combined with surgery
• Alveolar echinococcosis (E. multilocularis): 5-year mortality ~70% untreated; requires aggressive resection + long-term albendazole

ALA Complications

• Rupture into right pleural space, peritoneum, or pericardium
• Secondary bacterial superinfection
• Hepatobronchial fistula (rare)
• Portal hypertension (rare)

PLA Complications

• Rupture → purulent peritonitis (high mortality)
• Portal or hepatic vein thrombosis → portal hypertension, Budd-Chiari syndrome
• Pleural effusion / empyema (especially with abscesses >10 cm)
• Septicemia / septic shock
• Biliary fistula

• Current Surgical Therapy, 14th ed. — pp. 440–443
• Yamada's Textbook of Gastroenterology, 7th ed. — pp. 2178–2181
• Harrison's Principles of Internal Medicine, 22nd ed. — p. 1801
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease

Hydatid Cyst (Echinococcosis)

Etiology & Life Cycle

• Definitive host: dogs (and other canids) — adult tapeworm lives attached to the ileum; sheds up to 500 ova per day into feces
• Intermediate hosts: sheep, goats, cattle — ingest ova from contaminated grass/farmland
• Humans: accidental intermediate hosts — dead-end host; no human-to-human transmission

Cyst Structure & Pathology

Structure of echinococcal cyst showing pericyst, exocyst, endocyst, and protoscolices — Current Surgical Therapy 14e

• Hydatid sand: free-floating brood capsules and scolices in the cyst fluid
• Daughter cysts: true replicas of the mother cyst, developing from the germinal layer
• Calcification of the wall does not always imply the cyst is dead
• ~75% of cysts are located in the right lobe of the liver and are solitary

WHO-IWGE Classification (Ultrasound-Based)

WHO-IWGE ultrasound classification of echinococcal cysts — Current Surgical Therapy 14e

Clinical Presentation

• Dull RUQ pain / abdominal fullness
• Hepatomegaly
• Dyspepsia and nausea
• Abdominal distension

• Jaundice and cholangitis — rupture/communication with the biliary tree (occurs in up to ~⅓ of patients)
• Fever — bacterial superinfection mimicking a pyogenic abscess
• Productive cough / hemoptysis — rupture through the diaphragm into pleural cavity and lung
• Acute abdomen + anaphylactic shock — free rupture into the peritoneum (rare but life-threatening)
• Jaundice and fever each present in ~8% of patients overall

Diagnosis

Laboratory Tests

• Eosinophilia: ~30–40% of patients
• LFTs: normal or mildly elevated ALP/transaminases (unless biliary complication)
• ELISA (enzyme-linked immunosorbent assay): sensitivity 85–89% — has replaced older tests (Casoni skin test, complement fixation, indirect hemagglutination)
• Confirmatory: immunoblotting, antigen 5 and antigen B testing on hydatid cyst fluid
• Alveolar disease: Em2 antigen — 99% specificity for E. multilocularis; Em16/Em18 to distinguish active vs inactive

Imaging

• Simple cyst: well-circumscribed with budding signs; floating hyperechoic hydatid sand
• Daughter cysts: rosette/honeycomb appearance
• Calcifications: eggshell appearance — highly suggestive
• "Ball of wool" sign with degenerated membranes

(A) Simple hydatid cyst with hydatid sand. (B) Daughter and granddaughter cysts, rosette appearance. (C) Amorphous mass (semisolid). (D) Calcified eggshell appearance — Sabiston Textbook of Surgery

Differential Diagnosis

• Simple congenital hepatic cyst
• Amoebic abscess
• Pyogenic liver abscess
• Biliary cystadenoma / cystadenocarcinoma
• Hepatic metastasis with necrotic centre
• Polycystic liver disease

Treatment

Treatment Options Comparison

1. Medical Management (Benzimidazoles)

• Dose: 400 mg orally twice daily (≥60 kg); or 10–15 mg/kg/day divided twice daily (<60 kg), max 800 mg/day
• Better absorbed and concentrated in cyst fluid than mebendazole
• Duration: 3–6 months continuous (or perioperatively)
• Albendazole + praziquantel (25 mg/kg/day) is more effective than albendazole alone
• Side effects: neutropenia, hepatotoxicity, nausea, alopecia — monitor CBC and LFTs
• Monotherapy cure rate is low (cyst disappearance in well under 50%) — should be combined with procedural treatment
• Not indicated for inactive or densely calcified cysts (unless complicated)

2. PAIR (Percutaneous Aspiration-Injection-Reaspiration)

1. Percutaneous puncture and aspiration under ultrasound guidance
2. Aspiration of cyst contents
3. Injection of scolicidal agent (20% hypertonic saline or absolute alcohol) for 10–30 minutes
4. Re-aspiration and final irrigation with 0.9% saline

3. Surgical Management

• Large CE2–CE3 cysts with multiple daughter cysts
• Superficial cysts at risk of spontaneous or traumatic rupture
• Infected cysts or biliary communication (when PAIR unavailable)
• Mass effect on adjacent vital organs
• Failure of PAIR or medical management

1. Complete inactivation of scolices with scolicidal agents
2. Eliminate the parasite and viable cyst contents
3. Prevent spillage and recurrence
4. Manage the residual cyst cavity
5. Pack the field with hypertonic saline–soaked sponges before opening

• Best for peripherally located cysts
• Aspiration → injection of scolicidal agent → unroofing → removal of daughter cysts → resection of active cyst lining → omentoplasty
• If biliary communication present: close bile duct openings with absorbable sutures; pack with omentum; external closed-suction drainage if fistula cannot be closed

• Reduced hospital stay, shorter operating time, faster recovery
• Disadvantages: pneumoperitoneum increases spillage risk, limited manipulation, difficulty aspirating thick contents
• Conversion to open <5% in properly selected patients

• Complete resection of the cyst wall (open or closed technique)
• Closed pericystectomy: removes entire pericyst without entering cyst — lowest risk of spillage and recurrence
• Increased risk of bleeding and bile duct injury (~20% major morbidity)
• Best for peripheral cysts

• For alveolar echinococcosis (E. multilocularis), massive or centrally located cysts
• Lowest recurrence (~10%) but highest morbidity (~40%)
• Transplantation reserved for end-stage alveolar disease with hepatic failure

Complications

Alveolar Echinococcosis (E. multilocularis)

• Exclusively hepatic in 99% of cases
• Behaves like a malignant infiltrating tumour — no outer fibrous capsule, extends through liver parenchyma
• 5-year mortality ~70% untreated; 10-year mortality ~94%
• Requires radical surgical resection + long-term albendazole
• PNM staging system (analogous to TNM): P = parasite location/size in liver; N = neighbouring organ involvement; M = distant metastases (M0 vs M1)
• PET scan useful to identify active areas

• Current Surgical Therapy, 14th ed. — pp. 398–404
• Sabiston Textbook of Surgery, pp. 1891–1892
• Schwartz's Principles of Surgery, 11th ed. — p. 1551

Prevention of Liver Abscess & Hydatid Cyst Disease

I. Prevention of Amoebic Liver Abscess (ALA)

Sanitation & Water Safety

• Provision of safe drinking water and proper sewage disposal is the single most effective public health measure
• E. histolytica cysts are resistant to standard chlorination — disinfection by iodination (tetraglycine hydroperiodide tablets) is recommended in high-risk settings
• Use bottled water when travelling to endemic areas (Central/South America, Africa, South Asia)
• Avoid unpeeled raw fruits and vegetables in endemic regions (cysts survive on surfaces)
• Avoid ice made from potentially contaminated water

Personal Hygiene

• Strict handwashing with soap and water — especially after defecation and before food handling
• Food handlers with known E. histolytica infection should be excluded from work until cyst-free

Eradication of Cyst Carriage

• An asymptomatic carrier can excrete up to 15 million cysts per day
• Treatment of asymptomatic cyst passers with a luminal agent (paromomycin or iodoquinol) reduces community transmission
• All patients treated for ALA must also receive a luminal agent to eradicate intestinal cysts and prevent further transmission and relapse

No Vaccine

• There is currently no effective prophylactic vaccine against E. histolytica

II. Prevention of Pyogenic Liver Abscess (PLA)

Prompt Treatment of Source Infections

• Early diagnosis and treatment of biliary disease (cholelithiasis, cholangitis, cholecystitis) before progression to liver abscess
• Timely management of appendicitis and diverticulitis — before portal pyaemia develops
• Adequate treatment of periodontal / dental infections (haematogenous seeding)
• Effective management of inflammatory bowel disease and colorectal malignancy

Peri-procedural Measures

• Appropriate antibiotic prophylaxis before biliary instrumentation (ERCP, percutaneous biliary drainage, stent placement)
• Sterile technique during biliary and hepatic procedures
• Prompt biliary decompression when obstruction is identified

Risk Factor Control

• Tight glycaemic control in diabetic patients — diabetes is an independent risk factor
• Consideration of cryptogenic PLA: colonoscopy to exclude occult colorectal malignancy
• Caution with proton pump inhibitor use in patients with other risk factors — loss of gastric acid barrier may facilitate bacterial colonisation of the biliary tree
• Post-liver transplant patients: routine antifungal prophylaxis reduces fungal hepatic abscess risk

III. Prevention of Hydatid Cyst Disease (Echinococcosis)

Primary Prevention (Interrupting the Life Cycle)

Public Health & Community Measures

• Mass dog treatment programmes with praziquantel in endemic communities — the most effective population-level intervention
• Health education in endemic communities: explain the dog–sheep–human cycle and discourage feeding of raw offal to dogs
• Stray dog population control
• Surveillance and reporting of human cases to track endemicity

Personal Precautions (for Travellers / Exposed Individuals)

• Wash hands after contact with dogs, dog faeces, or contaminated soil
• Do not consume unwashed raw vegetables or herbs from areas where dogs defecate
• Drink safe water in endemic regions

Vaccination of Livestock

• EG95 vaccine for sheep (E. granulosus) — proven effective in reducing prevalence in intermediate hosts; used in national control programmes in New Zealand, Australia, and parts of South America. Vaccination of the main intermediate host (sheep) combined with dog deworming has achieved significant reductions in transmission in controlled programmes.

No Human Vaccine

• No licensed vaccine exists for humans. Prevention relies entirely on environmental and veterinary control.

Summary Table